Gilead Sciences (GILD.US) — market event timeline
NashNova tracks 1 market event mentioning Gilead Sciences (GILD.US) as of 2026-06-24, each with a dated one-line analysis of how the event relates to the asset.
- FDA Approves Gilead's Trodelvy for First-Line Treatment of Triple-Negative Breast Cancer
Trodelvy is a Gilead product, and the first-line indication approval directly expands its potential market size and revenue expectations.
For research and information only — not investment advice.